MedPath

Transversus Abdominus Plane Block in Living Donor Hepatectomy

Not Applicable
Completed
Conditions
Living Donor Hepatectomy
Interventions
Device: surgically inserted Transversus abdominus plane catheter
Drug: Bupevecaine
Drug: Dexmedetomedine
Registration Number
NCT02708459
Lead Sponsor
AlRefaey Kandeel
Brief Summary

Comparing different drugs used in Transversus abdominus plane analgesia after donor hepatectomy. Patients will be divided into three groups; control group, Bupivecaine group, and Dexmedetomedine group according to the used drug

Detailed Description

Transversus abdominus plane block for postoperative analgesia after donor hpatectomy surgery using three different drugs control group, Bupivecaine group, and Dexmedetomedine group

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • all living hepatectomy donors in Mansoura liver transplantation program
Exclusion Criteria
  • refusal known sensetivity to used drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dex groupIntravenous morphinecatheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
Dex groupsurgically inserted Transversus abdominus plane cathetercatheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
Dex groupDexmedetomedinecatheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
ControlIntravenous morphineControl group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
Bupevecaine groupsurgically inserted Transversus abdominus plane catheterPostoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
Bupevecaine groupIntravenous morphinePostoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
Bupevecaine groupBupevecainePostoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
Dex groupBupevecainecatheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
Primary Outcome Measures
NameTimeMethod
postoperative morphine (mg) consumption in 1st 48 hours48 hours postoperative
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mansoura university

🇪🇬

Mansoura, Dkahleya, Egypt

© Copyright 2025. All Rights Reserved by MedPath